ARTICLE | Clinical News
MG98: Began Phase I study
March 22, 1999 8:00 AM UTC
MethylGene Inc., Montreal, Quebec Product: MG98 Business: Cancer Therapeutic category: Antisense Target: DNA methyltransferase Description: Second generation antisense oligonucleotide targeting the ...